| Population 2013 |
21 million |
| |
| | | | |
| Estimates of TB burden * 2013 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
6.9 |
(3.5–9.9) |
32 |
(16–46) |
| Mortality (HIV+TB only) |
1.6 |
(1.1–2.1) |
7.3 |
(5.3–9.7) |
| Prevalence (includes HIV+TB) |
91 |
(45–150) |
423 |
(209–711) |
| Incidence (includes HIV+TB) |
69 |
(61–76) |
320 |
(286–353) |
| Incidence (HIV+TB only) |
7.5 |
(6.7–8.3) |
35 |
(31–39) |
| Case detection, all forms (%) |
85 |
(77–95) |
|
|
| |
| | | | |
| Estimates of MDR-TB burden * 2013 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
1.9 |
(0.1–5.3) |
20 |
(0.1–40) |
MDR-TB cases among notified pulmonary
TB cases |
920 |
(48–2 600) |
1 500 |
(8–3 000) |
| |
| | | | |
| TB case notifications 2013 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
21 661 |
|
5 353 |
| Pulmonary, clinically diagnosed |
26 758 |
|
0 |
| Extrapulmonary |
4 835 |
|
0 |
| |
|
|
|
| Total new and relapse |
58 607 |
|
|
| Previously treated, excluding relapses |
2 200 |
|
|
| Total cases notified |
60 807 |
|
|
| |
| | | | |
| Among 21 661 new cases: | | | | |
| 1 112 (5%) cases aged under 15 years; male:female ratio: 1.4 | | |
| | | | |
| Reported cases of RR-/MDR-TB 2013 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
0 (0%) |
232 (3%) |
232 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
232 |
| Patients started on MDR-TB treatment |
|
|
116 |
| |
| | | | |
| TB/HIV 2013 |
Number |
(%) |
| TB patients with known HIV status |
24 445 |
(40) |
| HIV-positive TB patients |
2 674 |
(11) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
2 674 |
(100) |
| HIV-positive TB patients on antiretroviral therapy (ART) |
|
|
| HIV-positive people screened for TB |
246 |
|
| HIV-positive people provided with IPT |
|
|
| |
| | | | |
| Treatment success rate |
(%) |
| New and relapse cases registered in 2012 |
45 |
| Previously treated cases, excluding relapse, registered in 2012 |
20 |
| HIV-positive TB cases, all types, registered in 2012 |
0 |
| RR-/MDR-TB cases started on second-line treatment in 2011 |
0 |
| XDR-TB cases started on second-line treatment in 2011 |
|
| |
| | | | |
| Laboratories 2013 |
|
| Smear (per 100 000 population) |
0.4 |
| Culture (per 5 million population) |
0.5 |
| Drug susceptibility testing (per 5 million population) |
0.5 |
| Sites performing Xpert MTB/RIF |
0 |
| Is second-line drug susceptibility testing available? |
Yes, outside
country |
| |
| | | | |
| Financing TB control 2014 |
|
| National TB programme budget (US$ millions) |
18 |
| % Funded domestically |
63% |
| % Funded internationally |
13% |
| % Unfunded |
24% |
| |
| | | | |
| * Ranges represent uncertainty intervals | | | |
| ** Includes cases with unknown previous TB treatment history | | |
| | | | |